3ChenW, ZhengR, ZengH, et al. Annual report on status of cancer in China, 2011[J]. Chin J Cancer Res, 2015, 27:2-12. DOI:10.3978/j.issn.1000-9604.2015.01.06.
4LogothetisCJ, LinSH. Osteoblasts in prostate cancer metastasis to bone[J]. Nat Rev Cancer, 2005, 5:21-28. DOI:10.1038/nrc1528.
5JemalA, SiegelR, XuJ, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60:277-300. DOI:10.3322/caac.20073.
6MottetN, BellmuntJ, BollaM, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer[J]. Actas Urol Esp, 2011, 35:565-579. DOI:10.1016/j.acuro.2011.03.011.
7HeidenreichA, PfisterD, PorresD. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study[J]. J Urol, 2015, 193:832-838. DOI:10.1016/j.juro.2014.09.089.
8HeidenreichA, BastianPJ, BellmuntJ, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013[J]. Eur Urol, 2014, 65:124-137. DOI:10.1016/j.eururo.2013.09.046.
9EsquivelJ, SticcaR, SugarbakerP, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology[J]. Ann Surg Oncol, 2007, 14:128-133. DOI:10.1245/s10434-006-9185-7.
10PolcherM, ZivanovicO, ChiDS. Cytoreductive surgery for advanced ovarian cancer[J]. Womens Health (Lond Engl), 2014, 10:179-190. DOI:10.2217/whe.14.4.
二级参考文献68
1Jemal A, Tiwari RC, Murray T, et al. American cancer society: cancer statistics 2004. CA Cancer J Clin, 2004, 54 : 8-29.
2Stephenson RA, Smart CR, Mineau GP, et al. The fall in inci- dence of prostate cancer: on the down side of a PSA induced peak in incidence. Cancer, 1996, 77: 1342-1348.
3Tarone RE, Chu KC, Brawley OW, et al. Implications of stage- specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology, 2000, 11 : 167-170.
4Ferlay J, Bray F, Pisani P, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55 : 74-108.
5Hankey BF, Feuer E J, Clegg LX, et al. Cancer surveillance se- ries : Interpreting trends in prostate cancer-part I : Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst, 1999, 91: 1017- 1024.
6Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer statistics review, 1975-2001, Bethesda, Md: National Cancer Institute, 2004: 120-124.
7Carroll P, Coley C, McLeod D, et al. Prostate specific antigen best practice policy-part II: prostate cancer staging and post- treatment follow-up. Urology, 2002, 57: 225-227.
8Neutel CI, Gao RN, Blood PA, et al. The changing age distribu- tion of prostate cancer in Canada. Can J Public Health, 2007, 98 : 60-64.
9Mottet N, Bellmunt J, Bolla M, et ah EAU gu tate cancer. Part Ⅱ: Treatment of advanced, rel idelines on pros- apsing, and cas- 2011. 59, 572-583.
10Mohler JL, Titus MA, Bai S, et al. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to di- hydrotestosterone in prostate cancer [ J]. Cancer Res, 2011, 15: 1486-1496.
